Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation monthly Stock Chart
Celgene Corporation
IndexS&P 500 P/E43.98 EPS (ttm)2.66 Insider Own0.20% Shs Outstand780.56M Perf Week-0.13%
Market Cap91.15B Forward P/E13.26 EPS next Y8.81 Insider Trans59.96% Shs Float778.77M Perf Month-5.80%
Income2.14B PEG2.12 EPS next Q1.78 Inst Own80.10% Short Float1.20% Perf Quarter-4.11%
Sales11.68B P/S7.81 EPS this Y28.10% Inst Trans0.65% Short Ratio2.65 Perf Half Y-3.37%
Book/sh9.81 P/B11.90 EPS next Y20.94% ROA7.80% Target Price141.71 Perf Year10.40%
Cash/sh11.35 P/C10.29 EPS next 5Y20.71% ROE33.60% 52W Range94.42 - 127.64 Perf YTD0.89%
Dividend- P/FCF34.07 EPS past 5Y11.80% ROI11.70% 52W High-8.51% Beta1.82
Dividend %- Quick Ratio4.20 Sales past 5Y18.30% Gross Margin96.20% 52W Low23.68% ATR1.77
Employees7132 Current Ratio4.40 Sales Q/Q17.90% Oper. Margin24.80% RSI (14)36.09 Volatility1.53% 1.42%
OptionableYes Debt/Eq1.87 EPS Q/Q17.00% Profit Margin18.30% Rel Volume0.72 Prev Close116.74
ShortableYes LT Debt/Eq1.80 EarningsApr 27 BMO Payout0.00% Avg Volume3.54M Price116.78
Recom1.90 SMA20-2.54% SMA50-4.74% SMA2001.13% Volume2,556,704 Change0.03%
May-05-17Downgrade Argus Buy → Hold
Mar-09-17Initiated UBS Buy $140
Nov-09-16Downgrade Standpoint Research Buy → Hold
Nov-08-16Initiated Mizuho Buy $130
Jul-15-16Initiated Stifel Buy $138
Apr-29-16Reiterated Sun Trust Rbsn Humphrey Buy $145 → $147
Feb-25-16Initiated Citigroup Buy $130
Jan-20-16Initiated Credit Suisse Outperform
Jan-14-16Initiated Standpoint Research Buy $130
Jan-08-16Initiated Sun Trust Rbsn Humphrey Buy $145
Jan-07-16Initiated Sun Trust Rbsn Humphrey Buy
Nov-06-15Reiterated UBS Buy $156 → $145
Oct-01-15Upgrade JP Morgan Neutral → Overweight
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $160
Jul-24-15Reiterated UBS Buy $142 → $156
Jul-24-15Reiterated JMP Securities Mkt Outperform $133 → $147
Jul-24-15Reiterated Cantor Fitzgerald Buy $146 → $163
Jul-21-15Reiterated Piper Jaffray Overweight $144 → $160
Jul-15-15Reiterated RBC Capital Mkts Outperform $135 → $150
May-28-17 09:40AM  3 Stocks the Market Is Wrong About Motley Fool
07:27AM  Better Buy: Celgene Corporation vs. Bristol-Myers Squibb Motley Fool
May-25-17 04:21PM  I Still Can't Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug Motley Fool
09:50AM  Short Sellers Raise the Stakes in Major Biotechs 24/7 Wall St.
09:30AM  The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene Zacks
07:36AM  Kyprolis Could Significantly Drive Amgens Revenue Growth in 2017 Market Realist
May-24-17 03:46PM  3 Healthcare Stocks for Savvy Investors Motley Fool
08:37AM  Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data Zacks
08:15AM  Blog Coverage: Celgene Reported Positive Late Stage Results from Trial of Ozanimod in Patients with Relapsing Multiple Sclerosis Accesswire
May-23-17 04:06PM  Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint Zacks
02:09PM  Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst Benzinga
01:07PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
May-22-17 04:15PM  Will Novartis' MS Drug Stomp Celgene's Before It Even Hits The Market? Investor's Business Daily
08:57AM  Celgene's multiple sclerosis drug succeeds in late-stage trial Reuters
08:20AM  Celgene Stock Rises Premarket on Positive Late-Stage Test Results for Multiple Sclerosis Treatment
08:03AM  Celgene reports positive results in trial of multiple sclerosis treatment MarketWatch
07:54AM  Celgene's multiple sclerosis drug succeeds in late-stage trial Reuters
07:30AM  Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis Business Wire
May-21-17 12:22PM  5 Leadership Lessons From Exceptionally Successful CEOs Motley Fool
09:03AM  Why Long-Term Investors Should Prefer Celgene Over Biogen Motley Fool
May-19-17 12:02PM  Why Stay Bullish On Gilead
08:00AM  Top 5 Biotech Stocks for 2017 Investopedia
May-18-17 01:01PM  3 Stocks To Buy When The Market's Crashing Motley Fool
May-17-17 05:41PM  Broad Range of Clinical Data Evaluating Celgene Therapies to Be Presented at American Society of Clinical Oncology (ASCO) Business Wire
05:10PM  Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting
05:02PM  Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract
05:00PM  Celgene leukemia drug extends survival in early stage trial Reuters
May-16-17 06:48PM  Cramer's lightning round: Buy this defense stock on fundamentals, not rumors CNBC
06:14PM  Celgene's (CELG) Revlimid Looks Solid on Label Expansion Zacks
May-14-17 10:00AM  3 Post-Earnings Biotech Buys
May-11-17 09:00AM  ONCYF: FDA Grants Fast Track Authority Zacks Small Cap Research
08:00AM  Today's Research Reports on Stocks to Watch: Allergan and Celgene Accesswire
12:00AM  4 of the Cheapest Biotech Stocks in the World Motley Fool
May-10-17 10:40AM  Major Biotech Short Interest Remains Mixed 24/7 Wall St.
May-09-17 09:30AM  Western Digital, Mattel, Celgene and Acceleron Pharma highlighted as Zacks Bull and Bear of the Day Zacks
08:00AM  Today's Research Reports on Trending Tickers: Celgene and Kite Pharma Accesswire
May-08-17 05:06PM  Why Shares of Biopharma Giant Celgene (CELG) Tumbled Today Zacks
04:50PM  Aadi Bioscience gets $23 million funding American City Business Journals
04:14PM  How Celgene Toppled On A Small-Cap Biotech's Ragged Quarter Investor's Business Daily
04:01PM  Why Acceleron Pharma Inc. Is Tumbling Today Motley Fool
02:57PM  BioMarin: Is Profitability On The Horizon?
11:42AM  [$$] Funding Snapshot: Aadi Bioscience Raises $23 Million Series A The Wall Street Journal
May-06-17 07:00AM  Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes Business Wire
May-05-17 04:31PM  Does Celgene Have Too May Eggs In One Drug Basket? Investor's Business Daily
04:04PM  Activision, Zillow Price Targets Hiked; Celgene, Lumentum Downgraded Investor's Business Daily
03:41PM  A Strong Case for Buying Celgene Motley Fool
01:53PM  Celgene: Too Much of a Good Thing?
01:27PM  Celgene Stock Falls Following Argus Downgrade
11:02AM  Juno Therapeutics Q1 Revenue Improves Thanks to Celgene Collaboration Motley Fool
08:46AM  Has Celgene Become Vulnerable To 'Revenue Concentration Risk'? Benzinga
08:16AM  Celgene Corp. breached its 50 day moving average in a Bullish Manner : CELG-US : May 5, 2017 Capital Cube
May-03-17 08:53AM  Celgene vs. Amgen: Which Stock is a Better Pick Post Q1 Earnings? Zacks
07:30AM  Celgene Corporation to Webcast at Upcoming Investor Conferences Business Wire
05:51AM  [$$] Four Small Biotechs See Bullish April Stock Buys
May-02-17 08:04AM  Celgene Corporation: The Bear Case From a Bull Motley Fool
May-01-17 02:52PM  What's in Store for Juno Therapeutics (JUNO) in Q1 Earnings? Zacks
01:21PM  Celgene CEO: The value of our medicines is priced into ho... CNBC Videos
10:53AM  Celgene Corp. :CELG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 1, 2017 Capital Cube
01:00AM  Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views
Apr-30-17 12:15PM  [$$] Cancer pill costs soar as drug companies retain pricing power Financial Times
08:00AM  Edited Transcript of CELG earnings conference call or presentation 27-Apr-17 1:00pm GMT Thomson Reuters StreetEvents
Apr-29-17 12:03PM  3 Top Biotech Stocks to Buy Now Motley Fool
Apr-28-17 04:20PM  Celgene Corporation Earnings: Trading Price for Volume Motley Fool
04:09PM  Vertex Big Winner In Biopharma Q1 As AbbVie, AstraZeneca Dip Investor's Business Daily
02:20PM  What's Worrying Me About Biogen Motley Fool
07:30AM  Today's Research Reports on Stocks to Watch: EXACT Sciences and Celgene Accesswire
07:20AM  Celgene CEO: Big supporters of trying to refine ACA Fox Business Videos
Apr-27-17 05:45PM  Alexion Beats On First-Quarter Sales; Profits Top By 15 Cents Investor's Business Daily
04:48PM  AbbVie Flirts With Buy Point After Q1 Earnings, Sales Top Investor's Business Daily
04:43PM  Celgene Dips On $95 Million Lag In Psoriasis Sales, But Earnings Top Investor's Business Daily
04:07PM  Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports
03:51PM  Three Biotechs EnterOne Biotech Gains
12:07PM  Biopharma earnings bonanza CNBC Videos
11:44AM  Celgene 1st quarter sales miss; expects psoriasis drug rebound Reuters
11:11AM  Celgene (CELG) Tops on Q1 Earnings, Sales Miss, Raises View Zacks
08:51AM  Biotech Earnings Roundup: Exact Sciences Flying Higher Investopedia
08:50AM  Celgene quarterly profit beats on Revlimid demand Reuters
08:13AM  Celgene (CELG) Beats On Q1 Earnings, Misses On Sales Zacks
07:44AM  Celgene tops 1Q profit forecasts Associated Press
07:35AM  Celgene quarterly profit rises 17.5 percent Reuters
07:27AM  Celgene Reports First Quarter 2017 Operating and Financial Results Business Wire
06:35AM  Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids
Apr-26-17 12:14PM  Time for Big Cap Biotech Investopedia
11:14AM  Celgene exec. chair: Trump administration will listen to ... CNBC Videos
09:40AM  Short Sellers Grow More Selective on Major Biotechs 24/7 Wall St.
08:04AM  Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY Zacks
08:04AM  The 1 Stock I'd Buy Right Now Motley Fool
07:20AM  Better Buy: Amgen Inc. vs. Biogen Motley Fool
Apr-25-17 10:07PM  [$$] Aquinnah Pharmaceuticals Taps Pfizer, AbbVie for $10 Million The Wall Street Journal
05:08PM  Fundstrat: 3 Nasdaq names to buy CNBC Videos
08:41AM  Key Factors to Look Out for in Celgene's (CELG) Q1 Results Zacks
07:04AM  Better Buy: Celgene Corporation vs. Merck & Co., Inc. Motley Fool
Apr-24-17 05:00PM  Celgene research leader Dr. Rupert Vessey joins Juno board American City Business Journals
03:17PM  Celgene (CELG) to Post Q1 Earnings: What's in the Cards? Zacks
03:13PM  Celgene Corp. Value Analysis (NASDAQ:CELG) : April 24, 2017 Capital Cube
01:02PM  Better Buy: Gilead Sciences vs. Celgene Motley Fool
08:21AM  9 Reasons Celgene Could Be the World's Most Perfect Stock Motley Fool
Apr-23-17 06:55PM  Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector
11:01AM  3 Stocks That Growth Investors Should Love Motley Fool
Apr-22-17 07:26AM  3 Top Stocks to Buy With Your Tax Refund Motley Fool
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; and Jounce Therapeutics, Inc.; The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LOUGHLIN JAMES JDirectorMay 01Option Exercise28.969,250267,88032,169May 02 04:20 PM
LOUGHLIN JAMES JDirectorMay 01Sale124.009,2501,147,00022,919May 02 04:20 PM
HUGIN ROBERT Jsee remarksApr 10Option Exercise29.0260,0001,741,200973,909Apr 12 04:24 PM
KAPLAN GILLADirectorMar 30Sale123.8314,0331,737,70673,109Mar 31 05:31 PM
KAPLAN GILLADirectorMar 03Option Exercise25.587,500191,81387,142Mar 07 04:37 PM
VESSEY RUPERTSee remarksMar 01Sale124.424,000497,672778Mar 02 04:04 PM
CASEY MICHAEL DDirectorFeb 27Option Exercise25.587,500191,8507,500Mar 01 04:15 PM
CASEY MICHAEL DDirectorFeb 27Sale121.557,500911,6250Mar 01 04:15 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62306,773Feb 06 04:14 PM
Celgene Switzerland LLC10% OwnerFeb 01Buy16.00625,00010,000,0003,456,463Feb 01 04:18 PM
HUGIN ROBERT Jsee remarksJan 05Option Exercise27.4322,708622,767913,909Jan 09 04:11 PM
Smith Scott AndrewSee RemarksDec 23Option Exercise0.006,400039,875Dec 27 04:17 PM
PEHL MICHAEL F.See remarksDec 02Option Exercise0.001,88001,880Dec 06 04:05 PM
Smith Scott AndrewSee RemarksDec 02Option Exercise0.003,750035,419Dec 06 04:05 PM
FOUSE JACQUALYN Asee remarksDec 02Option Exercise0.005,000084,392Dec 06 04:04 PM
Alles Mark JSee RemarksDec 02Option Exercise0.006,5600166,134Dec 06 04:03 PM
VESSEY RUPERTSee remarksNov 22Sale123.182,500307,9501,150Nov 30 04:15 PM
PEHL MICHAEL F.See remarksNov 10Option Exercise68.3920,4241,396,77022,052Nov 15 04:22 PM
PEHL MICHAEL F.See remarksNov 10Sale121.0422,0522,669,1490Nov 15 04:22 PM
Friedman Michael ADirectorNov 09Option Exercise31.8018,600591,48018,600Nov 10 04:14 PM
Friedman Michael ADirectorNov 09Sale116.1018,6002,159,4600Nov 10 04:14 PM
HUGIN ROBERT Jsee remarksNov 09Sale120.00100,00012,000,000922,201Nov 14 05:47 PM
CELGENE CORP /DE/10% OwnerOct 24Buy14.00800,15011,202,1004,834,980Oct 26 04:15 PM
CASEY MICHAEL DDirectorOct 18Option Exercise100.067,500750,45092,985Oct 19 04:16 PM
Friedman Michael ADirectorOct 03Option Exercise29.8656,1161,675,36456,116Oct 05 04:09 PM
Friedman Michael ADirectorOct 03Sale103.6656,1165,816,9850Oct 05 04:09 PM
BARKER RICHARD WDirectorSep 23Option Exercise36.9220,000738,40031,332Sep 26 04:08 PM
BARKER RICHARD WDirectorSep 23Sale110.8220,0002,216,40011,332Sep 26 04:08 PM
MARIO ERNESTDirectorSep 23Sale109.4215,0001,641,30090,058Sep 26 04:08 PM
KAPLAN GILLADirectorSep 19Option Exercise29.267,500219,45079,642Sep 20 04:42 PM
KAPLAN GILLADirectorSep 15Sale106.449,7101,033,53272,142Sep 16 04:15 PM
LOUGHLIN JAMES JDirectorAug 23Option Exercise26.3627,500724,85050,419Aug 24 04:28 PM
LOUGHLIN JAMES JDirectorAug 23Sale114.1027,5003,137,75022,919Aug 24 04:28 PM
CASEY MICHAEL DDirectorAug 22Sale114.0143,1344,917,70785,485Aug 23 04:29 PM
HUGIN ROBERT Jsee remarksJul 28Sale110.00100,00011,000,0001,022,201Aug 01 05:04 PM
MARIO ERNESTDirectorJul 01Option Exercise0.007330105,058Jul 05 04:32 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00733022,919Jul 05 04:30 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073300Jul 05 04:27 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00733081,852Jul 05 04:28 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00733023,146Jul 05 04:27 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00733011,551Jul 05 04:25 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073300Jul 05 04:26 PM
HUGIN ROBERT Jsee remarksJun 20Sale100.1675,0007,512,0001,122,201Jun 22 04:42 PM
KAPLAN GILLADirectorJun 17Option Exercise0.00333081,119Jun 17 04:18 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033300Jun 17 04:13 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033300Jun 17 04:14 PM
MARIO ERNESTDirectorJun 16Option Exercise0.002,0550113,892Jun 16 06:57 PM
COX CARRIE SMITHDirectorJun 16Option Exercise0.006,200022,413Jun 17 04:14 PM
KAPLAN GILLADirectorJun 15Option Exercise0.006,200080,786Jun 17 04:18 PM
LOUGHLIN JAMES JDirectorJun 12Option Exercise0.002,068021,853Jun 13 05:10 PM
MARIO ERNESTDirectorJun 12Option Exercise0.002,0680103,992Jun 13 05:10 PM
KAPLAN GILLADirectorJun 12Option Exercise0.002,068074,586Jun 13 05:09 PM
BARKER RICHARD WDirectorJun 12Option Exercise0.002,068011,439Jun 13 05:08 PM
CASEY MICHAEL DDirectorJun 12Option Exercise0.002,06800Jun 13 05:08 PM
Friedman Michael ADirectorJun 12Option Exercise0.002,06800Jun 13 05:09 PM